Brazil’s Eurofarma Teams With Japan’s Eisai to Bring the Insomnia Drug Dayvigo to Market
Brazil · Business
Key Facts
- —The deal Eurofarma has partnered with Japan’s Eisai to bring the insomnia drug lemborexant, sold as Dayvigo, to Brazil, per Valor Econômico on 17 August 2026.
- —The drug lemborexant is an orexin receptor antagonist, a newer type of sleep medicine that works differently from older sleeping pills.
- —The status Brazil’s regulator Anvisa has already registered Dayvigo; a commercial launch still waits on a price ruling from the CMED board.
- —The market Brazil’s insomnia-treatment market moves about R$1.3 billion, roughly US$240 million, a year.
- —The partners Eurofarma is São Paulo’s largest Brazilian-owned drugmaker; Eisai is a Tokyo firm known for the Alzheimer’s drug Leqembi.
The deal pairs Japan’s newest sleep science with Brazil’s biggest homegrown drug sales force. Aimed at a market worth about US$240 million a year.
Brazil’s Eurofarma has struck a partnership with Japan’s Eisai to bring a new insomnia drug to the country’s pharmacies. The medicine is lemborexant, sold under the brand Dayvigo, a sleeping pill that works in a fresh way.
Business daily Valor Econômico reported the deal on 17 August 2026.
What Eurofarma and Eisai Agreed
Eurofarma said it closed a partnership with Eisai to sell Dayvigo in Brazil. The Japanese firm developed the drug, while the Brazilian company brings the local reach.
In short, Eisai supplies the science and Eurofarma supplies the sales muscle. That division of labour matches how the two firms have worked before.
The companies have not spelled out the fine print in public. As a result, the exact shape of the deal, and any money changing hands, remains undisclosed.
How Dayvigo Works
Dayvigo is the brand name for lemborexant, a molecule that targets the brain’s wake system. It blocks orexin, a chemical that keeps people alert.
Because it quiets the signal that keeps you up, sleep is meant to follow more naturally. That is a different route from most pills on the shelf today.
Why the New Mechanism Matters
Older sleeping pills, such as benzodiazepines and so-called Z-drugs, work by broadly sedating the brain. However, they can bring dependence and grogginess.
Lemborexant instead switches off a single wake pathway. For that reason, doctors expect less dependence and fewer hangover effects, though real-world use will tell.
The drug even drew notice abroad for its design. Still, no medicine is risk-free, and patients need a doctor’s guidance.
Where the Drug Stands With Regulators
This is not a plan for some distant approval. Anvisa, Brazil’s health regulator, has already registered Dayvigo for sale.
Even so, the pill is not on pharmacy shelves yet. Before it sells, Brazil’s CMED price board must set a maximum price.
Neither company has named a launch date. Therefore, the timing of the first sale still depends on that pricing step.
The Brazilian Market Eurofarma Is Chasing
Sleepless nights are big business in Brazil. The country’s insomnia-treatment market moves about R$1.3 billion, roughly US$240 million, each year.
That figure explains the appeal of a fresh product. Because demand is steady and large, a novel pill can carve out real share.
Insomnia is also widespread and often untreated. As a result, both firms see room to grow the category, not just split it.
Who Eurofarma Is
Eurofarma is based in São Paulo and ranks among Brazil’s largest homegrown drugmakers. It also sells across much of Latin America.
That footprint is exactly what a foreign partner wants. In short, Eurofarma can push a drug through Brazil’s crowded pharmacy network fast.
The company has long paired local reach with outside science. Meanwhile, it keeps building its own pipeline at home.
Who Eisai Is
Eisai is a Japanese pharmaceutical company headquartered in Tokyo. It researches and develops medicines and sells them worldwide.
The firm is best known lately for Leqembi, an Alzheimer’s treatment it developed with a partner. Lemborexant is another of its in-house discoveries.
Japan’s drugmakers often lean on local partners abroad. For example, Eisai has used exactly this model in Brazil before.
A Partnership With History
This is not the first Eurofarma deal for Eisai. Back in 2018, the two teamed up on the anti-obesity drug lorcaserin.
In that case, Eisai granted Eurofarma exclusive marketing rights in Brazil and in 17 other Latin American markets. The firms also worked together earlier on a cancer treatment.
So the insomnia deal builds on a familiar template. Because the relationship is established, adding a new drug is a smaller leap.
What Is Still Unclear
The public report is thin on terms. It confirms the partnership and the market size, but little else.
It does not say whether the deal is exclusive, nor how the two firms split the work. Any financial figures stay private for now.
The scope also reads as Brazil-focused. However, the companies have not ruled out a wider regional push later.
What Comes Next
The next milestone is a price. Once CMED sets the ceiling, Eurofarma can schedule a launch.
After that, the test is uptake. Because patients and doctors are cautious with new sleep drugs, adoption may build slowly.
For now, though, the headline is simple. A modern insomnia pill is heading toward Brazilian pharmacies, backed by a proven local partner.
Frequently Asked Questions
What did Eurofarma and Eisai agree to do?
Eurofarma partnered with Japan’s Eisai to bring the insomnia drug lemborexant, sold as Dayvigo, to Brazil. Eisai developed it; Eurofarma handles local sales.
How is Dayvigo different from other sleeping pills?
Dayvigo, or lemborexant, blocks orexin, a chemical that keeps the brain awake. Older pills broadly sedate the brain, which can cause more dependence.
Is the drug already for sale in Brazil?
Not yet. Anvisa has registered Dayvigo, but a launch waits on Brazil’s CMED price board setting a maximum price.
How big is Brazil’s insomnia market?
Brazil’s insomnia-treatment market moves about R$1.3 billion, roughly US$240 million, a year, according to Valor Econômico.
Connected Coverage
Sources: Valor Econômico; O Globo; Eisai; Anvisa; The Pharma Letter.
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error
Read More from The Rio Times